Isola Therapeutics

Isola Therapeutics is a private preclinical-stage biopharmaceutical and medical device company developing endoluminal local drug delivery systems for severe diseases, with an initial focus on oncology. Its technology is designed to deliver high concentrations of therapeutics directly to tissue lining hollow organs while minimizing systemic exposure and toxicity. Publicly described applications include esophageal cancer and other lung or acute respiratory indications, and the company positions the platform as compatible with chemotherapy, hormonal therapy, and targeted or biologic drugs. Isola appears to be an early-stage platform company headquartered in Minneapolis, Minnesota, supported by non-dilutive funding and accelerator participation.